Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab for High-risk Non-muscle Invasive Bladder Cancer Failing BCG Treatment
NCT04706598Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Jun 2021
- Primary completion
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in Non-muscle-invasive bladder cancer (NMIBC), sponsored by Fudan University. Started Jun 2021; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
Non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04706598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04706598.